The Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association

Similar documents
The Shifting Federal Regulation of Cannabis Products

Does Legality equal Legitimacy? The challenges of fostering safe practice with state legalization of marijuana

Changing the Drug Enforcement Administration (DEA) Schedule of Tetrahydrocannabinol (THC), Cannabidiol and Combinations to Promote Research

Office of University Counsel and Secretary of the Board of Regents

Medical Cannabis MATT WEBSTER DO, MS

Federal Law: Marijuana

Maine s Medical Marijuana Law. 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 1030

Outcome. Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C

Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C

Substitute HB 523 Outline

ENROLLED 2014 Legislature CS for CS for SB 1030, 1st Engrossed

Medical Marijuana. Navigating Medical Marijuana in Workers Compensation

Oregon State University Guidance on Cannabis Research, Teaching, and Outreach Activities

Understanding Maine s Medical Marijuana Law

MINNESOTA S MEDICAL CANNABIS PROGRAM

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Is the most common illicit drug used in the United States. After a period of decline in the last decade, its use has been increasing among young

A look at Marijuana in 2014

Begun and held at the City of Washington on Friday, the twentieth day of April, two thousand and eighteen. JOINT RESOLUTION

MEDICAL MARIJUANA: Can Cannabis Still Get You Canned?

Compassionate Medical Cannabis: What It Means to the Street Officer

Policy \ \ Medical (Palliative) Use of Marijuana

Medical Marijuana Update Chris Belletieri, DO

PATIENT INTAKE FORM. Name: Address: Town: State: Zip Code: MMJ Card #: Exp. Date: Drivers License #: Exp. Date: Home Phone: Cell:

Coordinated Student Health Services. Medical Marijuana/ Low THC Cannabis Use To Qualified Students In Schools Policy

MEDICAL CANNABIS IN MINNESOTA

Doris C. Gundersen MD Medical Director Colorado Physician Health Program Colorado Association of Medical Staff Services Conference Estes Park,

From heroin to medical marijuana: what districts need to know Megan Greulich, Staff Attorney Hot Topics in School Law October 5, 2016

December 2018 Brief Explanation of Proposition 2 and Compromise Bill Passage

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system

North Central Florida Regional Planning Council

An HR Perspective: Medical Marijuana and How it Affects Employers

8/31/2016. Workplace Implications of Marijuana in the US. Goal

The Legalization of Medical Marijuana and the Impact on the Workplace

Navigating the Rapidly Changing World of Marijuana and the Workplace. January 16, 2018

The State of Cannabis in Oregon

MICHIGAN MEDICAL MARIJUANA REGULATION: From Home Remedy to Criminalization. to State Regulated Industry. March 22, Stephen K.

Ohio s Medical Marijuana Control Program

The Marijuana Law Trend and Resulting Impact on Healthcare Providers

Medical Cannabis Ordinances. Tuesday, December 20, 2016

SECTION V: EMPLOYEES POLICY 5375 MEDICAL MARIJUANA, HEMP & CANNABIDIOL (CBD)

78th OREGON LEGISLATIVE ASSEMBLY Regular Session. Senate Bill 964 SUMMARY

MEDICAL CANNABIS IN MINNESOTA

Torkin Manes LegalPoint

Marijuana and the Workplace : Changing Times

This questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level.

ADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP

MEDICAL MARIJUANA AND HEALTH CARE FACILITIES

THE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL AN ACT

Medical Marijuana and Student Health. New England College Health Association Gordon H. Smith, Esq. October 30, 2014

Clinical Education Initiative MEDICAL MARIJUANA 101. Speaker: Patricia Reed, PharmD

WELCOME TO THEORY WELLNESS CUSTOMERS. Committed to wellbeing through cannabis.

INITIAL PATIENT INTAKE FORM

MARIJUANA IN THE PUBLIC WORKPLACE PHILIP A. TOOMEY

TEXAS COMPASSIONATE-USE ACT

AN ORDINANCE OF THE BOARD OF COUNTY

Act 16 and Medical Cannabis in Pennsylvania

Medical Marihuana for Patients in the Lymphoma Setting. Speakers: Ruth Turner, RN, Con Rob Laister, PhD

COMIRB Protocol Number: PI: Madeline Cole, MS-III Michael Chan, MS-III Dan Matlock, MD MPH. Dear Fellow Medical Student,

Use of Cannabinoids in Medical Practice

Research: Medical Cannabis

POLICY NUMBER: POL 153

Cannabis Research at UCLA

Curious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

RECREATIONAL CANNABIS LEGALIZATION IN ONTARIO

LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018

Workplace Issues Associated with Legalized Marijuana. James B. Yates, Esq., SHRM-SCP, SPHR

Medical Marijuana: Coverage Considerations for the Buckeye State. ISCEBS & CSHRM Education Session April 20, 2018

CANNABIS FOR THE RHEUMATOLOGIST

MARIJUANA PREVENTION TOOLKIT KNOW THE FACTS

Medical Marijuana: Current Policies and Consideration. By Michael Bertaut Healthcare Economist, BCBSLA 2019

Weeding Through the Workplace Impact of Medical Marijuana

Legalized Marijuana: Uses, Misuses & Abuses. Disclosures. Objectives. Kennon Heard University of Colorado SOM Dept Of Emergency Medicine

Policy / Drug and Alcohol-Free Workshops

79th OREGON LEGISLATIVE ASSEMBLY Regular Session. Senate Bill 1015 SUMMARY

These documents were created to support the work of the Coalition of Colorado Campus Alcohol and Drug Educators. We welcome prevention teams at

Cannabis in the Workplace: Lessons Learned. Sponsored by:

PFC Training Courses & Programs. Course Descriptions. 1. Core Cannabis Training (CCT) [pre-requisite for all PFC Courses]

Oncology Pharmacy Navigator: A Novel Model for Medication Management

MEMORANDUM INTRODUCTION. DATE: July 28, 2016; Revised August 3, 2016 TO:

Please note that this draft is incomplete and likely to change before and/or after City Planning Commission review.

2018 Farm Bill to Lift Federal Prohibition on Hemp Production, but State Laws May Restrict Certain Activities

Rental Addendum Prohibiting Smoking

MEDICAL MARIJUANA/LOW THC CANNABIS USE TO QUALIFIED STUDENTS IN SCHOOLS

Questionnaire 1 of 5: Cannabis Plant and Cannabis Resin. Introduction

THOUGHTS FROM WASHINGTON STATE

SENATE BILL No. 676 AMENDED IN SENATE APRIL 28, 2011 AMENDED IN SENATE MARCH 31, Introduced by Senator Leno.

9/28/2015. Support. R01CA A1 Intervening with smoking parents of inpatients to reduce

CDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only

THE STATE OF THE STATES-A REPORT ON MEDICAL CANNABIS PROGRAMS MID YEAR MEETING AND SCIENTIFIC SEMINAR APRIL 13, 2018 NASHVILLE, TENNESSEE DEBBY MIRAN

SUNRISE, FLORIDA ORDINANCE NO.

AGENDA. 9:00 Sign-in and introductions 9:15 Marijuana 10:30 Break 10:45 Opioid Prevention 11:30 Discussion & Wrap-Up

AZ s Medical Marijuana Law Overview and Considerations. Ryan Hurley Partner, Chair of MMJ Dept. Rose Law Group pc

REGULATION TO ENSURE THE SANITARY AND SAFE OPERATION OF ADULT-USE MARIJUANA ESTABLISHMENTS AND THE SALE OF ADULT-USE MARIJUANA

Final Report of the. (HB 151, Chapter 17:1, Laws of 2018) October 16, Membership. Rep. Peter W. Bixby, Clerk Rep. Howard Pearl.

MEDICAL MARIJUANA PLANNER S PORTFOLIO

Marijuana Law. Selected Legal Issues. Brian N. Morrow, Esq.

MARIJUANA LEGALIZATION. INITIATIVE STATUTE.

Transcription:

The Sale of Cannabis in Pharmacies Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association

Development This activity was developed by the American Pharmacists Association.

How to Claim Credit Go to www.pharmacist.com/live activities and under the Live Activities list, select Claim Credit link for: APhA Policy Topic: The Sale of Cannabis in Pharmacies You will need to enter your pharmacist.com Username and Password. If you do not have an account, you can create a guest account for free. Then, continue with the following instructions to obtain your CPE credit for this activity. Select Add to Cart or Enroll Now from the left navigation and successfully complete the Assessment and Evaluation. You will need to provide your NABP e profile ID number to claim credit.

Accreditation Information The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity, APhA Policy Topic: The Sale of Cannabis in Pharmacies, is approved for 0.5 hours of continuing pharmacy education credit (0.05 CEUs). The ACPE Universal Activity Number assigned by the accredited provider is: 0202 0000 14 175 L04 P. To obtain continuing pharmacy education credit for this activity, participants will be required to actively participate in the entire webinar and complete an assessment and evaluation located at www.pharmacist.com/live activities by November 4, 2014. Target Audience: Pharmacists ACPE Activity Type: Knowledge based Learning Level: 1 Fee: There is no fee for this activity

Disclosures Michael H Ghorbial, PharmD, JD is employed by the American Pharmacists Association. All APhA staff declare no conflicts of interest in any products or service mentioned, including grants, employment, gifts, stock holdings, and honoraria.

Learning Objectives Upon completion of these knowledge based activities, the pharmacist will be able to: 1. Describe the pharmacologic and therapeutic differences of the various formulations of cannabis, available scientific evidence and the potential impact on patients. 2. Discuss issues regarding the sale of cannabis in pharmacies and potential roles, if any, for pharmacists. 3. Review the legal and ethical implications related to dispensing cannabis in community pharmacies.

Assessment Question 1 Which of the following states has placed pharmacists in a key role of dispensing inhaled cannabis? a. Washington b. Connecticut c. New York d. Colorado

Assessment Question 2 Under Federal law, inhaled cannabis is a Schedule Controlled Substance, while the orally ingested formulation (dronabinol) is a Schedule Controlled Substance. a. I, II b. I, III c. II, III d. II, IV

Assessment Question 3 Which isomer of tetrahydrocannabinol (THC) is responsible for the majority of psychological effects of cannabis? a. 6a,7 THC b. 7 THC c. 9 THC d. 10 THC

Background Information Marijuana is a mixture of dried shredded flowers and leaves of the hemp plant Cannabis sativa. Other preparations include Keif, Hashish (resin), Tinctures, Oils, and Butters Preparations such as oils and resins can contain THC concentrations of up to 60% which is substantially higher than the 5% commonly seen in the dried and shredded flower Cannabis contains chemicals called cannabinoids and several isomers of tetrahydrocannabinol (THC). 9 THC is the active ingredient responsible for the majority of the psychological effects of cannabis. Potency depends on the concentration of THC. Dronabinol (Marinol ) is a synthetic 9 THC product. Only FDA approved THC product on the market today

Tetrahydrocannabinol (THC) Pharmacological Effects of THC Increase pulse rate Decrease blood pressure Muscle weakening Increases appetite, Causes euphoria Decreases memory recollection and learning Medical Uses of THC Muscle spasms caused by MS Seizures Crohn s disease Chronic pain Nausea Useful for patients receiving chemotherapy. Appetite Stimulation Useful for poor appetite and weight loss in patients with advanced human immunodeficiency virus (HIV) Glaucoma Decreases IOP

Background Information Marijuana is usually inhaled or ingested orally Inhaled products can be smoked or vaporized Oral products consist of drinks such as teas and edibles Inhaled cannabis has been shown to provide a rapid and efficient delivery of THC to the brain. THC can be detected in the plasma immediately and peak plasma concentration can be seen within 10 minutes. Absorption of THC from the gut after oral ingestion of cannabis is much slower. Oral ingestion produces a delayed peak plasma concentration of THC compared to inhaled formulations. Other forms include oils

The Sale of Cannabis in Pharmacies Overview Contradiction between state and federal law Efficacy, safety and patient care issues Pharmacists role in the provision of medical/recreational cannabis Pharmacists role in patient education, screening and monitoring Social aspects of recreational marijuana use

Background Information The Controlled Substance Act was signed into law in 1970 by President Richard Nixon, and the legislation defined different classes based upon physical dependence, abuse potential and appropriate medical use. Scheduled I Substances are defined as substances that have a high potential for abuse, have no current medical use in the United States of America, and have a lack of accepted safety when used under medical supervision. (Marijuana/Cannabis, Hashish) Schedule III Controlled Substances have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence. (Dronabinol or Marinol )

Background Information Medicinal: Indicated for the treatment of a medical condition Recreational: Marijuana is used for its mood altering effects, euphoria, and relaxation. 23 states and Washington D.C. have laws and regulations that permit use of medicinal marijuana Two states (Colorado & Washington) have written legislation to decriminalize the recreational use of marijuana

Connecticut Medical Marijuana State Bill of 2012 Prescribers will need to certify patients medical need for the drug before it will be dispensed Patients must register with the Connecticut Department of Consumer Protection Restricts patients to obtain medical marijuana from licensed dispensaries A dispensary is a licensed pharmacist who the Department of Consumer Protection determines to be qualified to acquire, possess, distribute and dispense marijuana Immunity from state prosecution A dispensary must only purchase marijuana products from licensed producers

Variation of State & Federal Laws While various states have allowed the use of inhaled cannabis for medical purposes, federal regulation still classifies inhaled cannabis as a Schedule I Controlled Substance indicating the federal government recognizes no medical use. In terms of compliance with both state and federal statues, pharmacists must comply with the law that is most stringent, in this case recognizing inhaled cannabis as a Schedule I Controlled Substance. Violation of federal statues can result fines, imprisonment and/or the revocation of the pharmacy s DEA registration, immediately halting the dispensing of controlled substances.

Pharmacists clinical concerns with the use of Medical Marijuana as a treatment option Product variability in between growers/producers Limited efficacy and safety data Lack of scientific data on inhaled cannabis and lack of guidance by the FDA leaves pharmacists ill prepared to make clinically sound decisions when assessing cannabis therapy and inhibits pharmacists ability to educate patients. Legal liability stemming from federal regulation Pharmacists are hesitant to jeopardize their careers by being involved in dispensing inhaled cannabis

Perspective from AMA 1. Our AMA calls for further adequate and well controlled studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease. 2. Our AMA urges that marijuana s status as a federal schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid based medicines, and alternate delivery methods. This should not be viewed as an endorsement of state based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product. 3. Our AMA urges the National Institutes of Health (NIH), the Drug Enforcement Administration (DEA), and the Food and Drug Administration (FDA) to develop a special schedule and implement administrative procedures to facilitate grant applications and the conduct of well designed clinical research involving cannabis and its potential medical utility Policy updated in 2009 and reaffirmed in 2013.

Role of Pharmacists As with any substance for medical use, Pharmacists are expected to complete a prospective drug utilization review (DUR) to assess: Appropriateness of Therapy Appropriate Drug, Dose, Route and Duration Allergies & Drug Interactions Contraindications Abuse & Misuse

Role of Pharmacists Pharmacists are also expected to provide patient education and counseling. Lack of a credible data causes serious challenges for pharmacists to perform their responsibilities as a pharmacist and advocate for appropriate patient care. Pharmacists are in a unique position to be dispensers and educators of Cannabis. Pharmacists must be aware of how cannabis use affects patients, including cognitive effects and drug interactions.

Conclusions Inhaled cannabis has very limited published literature on its therapeutic use, but in the literature that is present, efficacy has been shown. However, use of inhaled cannabis has a litany of adverse effects that raise patient safety issues. Currently, over twenty states have legalized medical marijuana use, with two of them ceasing to treat the recreational use of marijuana as illegal. Federal law still states that marijuana is a Schedule I drug. Consistency in quality and purity remain a concern for pharmacists

Conclusions There are potential safety concerns for pharmacists and their staff associated with an increase risk for burglaries and robberies working in dispensaries that stock inhaled cannabis. Currently, Connecticut is the only state in which a pharmacist dispenses inhaled cannabis for medical use. Connecticut could be viewed as a model for other states evaluating the role of pharmacists in dispensing inhaled cannabis for medical purposes.

Related APhA Policy 1980 Medicinal Use of Marijuana* 1. APhA supports research by properly qualified investigators operating under the investigational new drug (IND) process to explore fully the potential medicinal uses of marijuana and its constituents or derivatives. 2. APhA opposes state by state, marijuana specific, or other drug specific legislation intended to circumvent the federal laws and regulations pertaining to (a) marketing approval of new drugs based on demonstrated safety and efficacy, or; (b) control restrictions relating to those substances having a recognized hazard of abuse. *Reviewed and reaffirmed in 2011

Related APhA Policy 2003, 1983 The Use of Controlled Substances in the Treatment of Intractable Pain 2012 Controlled Substance Regulation and Patient Care 2014 Controlled Substances and Other Medications with the Potential for Abuse and Use of Opioid Reversal Agents

Assessment Question 1 Which of the following states has placed pharmacists in a key role of dispensing inhaled cannabis? a. Washington b. Connecticut c. New York d. Colorado

Assessment Question 2 Under Federal law, inhaled cannabis is a Schedule Controlled Substance, while the orally ingested formulation (dronabinol) is a Schedule Controlled Substance. a. I, II b. I, III c. II, III d. II, IV

Assessment Question 3 Which isomer of tetrahydrocannabinol (THC) is responsible for the majority of psychological effects of cannabis? a. 6a,7 THC b. 7 THC c. 9 THC d. 10 THC

QUESTIONS?

What s your perspective? What do you envision as pharmacists role? Dispensing, counseling, etc. What are the major patient care challenges related to the use of medical and/or recreational marijuana? How should APhA s policy address the various forms of cannabis?

How to Claim Credit Go to www.pharmacist.com/live activities and under the Live Activities list, select Claim Credit link for: APhA Policy Topic: The Sale of Cannabis in Pharmacies You will need to enter your pharmacist.com Username and Password. If you do not have an account, you can create a guest account for free. Then, continue with the following instructions to obtain your CPE credit for this activity. Select Add to Cart or Enroll Now from the left navigation and successfully complete the Assessment and Evaluation. You will need to provide your NABP e profile ID number to claim credit.

National Drug Monitoring Program TOMORROW! October 22, 2014 1:00pm to 2:00pm ET Sign up at www.pharmacist.com/hod

Thank You! Contact HOD Staff or Submit additional comments/questions HOD@aphanet.org www.pharmacist.com/hod